214 Prognostic Value of Post Focal Therapy PSA Metrics in Prediction of Outcomes for Salvage Focal Therapy for Radiorecurrent Prostate Cancer
British Journal of Surgery · 10.07.2026 · 113 (Supplement_6)
DOI: 10.1093/bjs/znag063.737 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 10.07.2026. Verfasst von R D Patel und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Aim
Salvage focal therapy is a less-morbid option for radiorecurrent prostate cancer, but PSA-based response criteria are undefined. We evaluated whether 12-month PSA metrics predict oncological outcomes and aimed to establish a practical biochemical failure threshold.
Method
Men treated with focal high-intensity focal ultrasound (HIFU) or focal cryotherapy for radiorecurrent prostate cancer between 2017-2024 were identified from the HEAT and ICE prospective registries. From the 12-month landmark, Kaplan-Meier analysis and multivariable Cox regression were used to assess whether 12-month PSA predicted treatment failure (metastasis, local retreatment excluding one redo salvage focal therapy, initiation of androgen deprivation therapy or cancer-specific death) and was adjusted for age, pre-salvage grade group, and salvage treatment modality. The 12-month PSA value that provided the maximal sensitivity and specificity for predicting the outcome (Youden’s index) was calculated.
Results
85 patients were included who underwent focal HIFU (n=52) or focal cryotherapy (n=33) between 2017-2024. Median follow-up was 24.6 months. Median baseline PSA was 5.20 ng/mL and median 12-month PSA was 0.92 ng/mL. 5-year failure-free survival was 0.43 (95%CI 0.30-0.61, p=0.035) from the point of salvage treatment. 12-month PSA was independently associated with treatment failure (HR1.17 per 1.0 ng/mL increase, 95%CI 1.01-1.35, p=0.04). An absolute PSA value of ≥1.09 ng/mL for the 12-month PSA provided 63.0% sensitivity and 70.6% specificity for predicting treatment failure.
Conclusions
An exploratory 12-month PSA threshold of ≥1.09 ng/mL demonstrated moderate sensitivity and specificity for predicting treatment failure and requires validation in larger cohorts.
Zitieren
APA
Patel, R. D., Gopalakrishnan, A., Mayor, N., Bertoncelli-Tanaka, M., Arya, M., Ahmed, H. U., Shah, T. T., & Light, A. (2026). 214 Prognostic Value of Post Focal Therapy PSA Metrics in Prediction of Outcomes for Salvage Focal Therapy for Radiorecurrent Prostate Cancer. British Journal of Surgery, 113(Supplement_6). https://doi.org/10.1093/bjs/znag063.737
Vancouver
Patel RD, Gopalakrishnan A, Mayor N, Bertoncelli-Tanaka M, Arya M, Ahmed HU, et al. 214 Prognostic Value of Post Focal Therapy PSA Metrics in Prediction of Outcomes for Salvage Focal Therapy for Radiorecurrent Prostate Cancer. British Journal of Surgery. 2026;113(Supplement_6). doi:10.1093/bjs/znag063.737
BibTeX
@article{Patel2026,
author = {Patel, R D and Gopalakrishnan, A and Mayor, N and Bertoncelli-Tanaka, M and Arya, M and Ahmed, H U and Shah, T T and Light, A},
title = {214 Prognostic Value of Post Focal Therapy PSA Metrics in Prediction of Outcomes for Salvage Focal Therapy for Radiorecurrent Prostate Cancer},
journal = {British Journal of Surgery},
year = {2026},
volume = {113},
number = {Supplement_6},
doi = {10.1093/bjs/znag063.737}
}
EUVIMED